AstraZeneca PLC (AZN)
| Market Cap | 238.71B |
| Revenue (ttm) | 47.61B |
| Net Income (ttm) | 6.33B |
| Shares Out | 3.10B |
| EPS (ttm) | 2.03 |
| PE Ratio | 37.82 |
| Forward PE | 16.31 |
| Dividend | $1.45 (1.88%) |
| Ex-Dividend Date | Feb 22, 2024 |
| Volume | 3,003,590 |
| Open | 77.31 |
| Previous Close | 77.94 |
| Day's Range | 76.46 - 77.42 |
| 52-Week Range | 60.47 - 80.86 |
| Beta | 0.17 |
| Analysts | Buy |
| Price Target | 87.25 (+13.33%) |
| Earnings Date | Jul 25, 2024 |
About AZN
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus... [Read more]
Financial Performance
In 2023, AstraZeneca's revenue was $45.81 billion, an increase of 3.29% compared to the previous year's $44.35 billion. Earnings were $5.96 billion, an increase of 81.11%.
Financial StatementsAnalyst Forecast
According to 7 analysts, the average rating for AZN stock is "Buy." The 12-month stock price forecast is $87.25, which is an increase of 13.33% from the latest price.
News
AstraZeneca's COVID prevention drug application gets EU fast-track assessment
AstraZeneca said on Monday the EU drug regulator has accepted a market authorisation application for its investigational COVID-19 prevention drug, Sipavibart, under an accelerated assessment.
German vaccine panel endorses Astra-Sanofi's RSV shot for infants
Germany's influential vaccine advisory panel said on Thursday all infants in the country should receive AstraZeneca and Sanofi's antibody therapy to protect them against the common respiratory infecti...
Healthcare: Best strategies to invest in pharma stocks
Novo Nordisk (NVO) and Eli Lilly (LLY) both made headlines recently with positive drug trial results for their respective GLP-1 weight-loss drugs, as well as their approval in China. While these names...
Tanium Plays Critical Role in Supporting AstraZeneca's Mission to Deliver Life-Changing Medicines
KIRKLAND, Wash.--(BUSINESS WIRE)--Tanium today shared the success story of customer AstraZeneca in securing over 125,000 endpoints across 125 countries using the Tanium XEM platform.
China approves AstraZeneca's Tagrisso-chemo combo as first-line treatment
China has approved the use of AstraZeneca's blockbuster cancer drug Tagrisso in combination with chemotherapy as a first line of treatment for adults with a type of advanced lung cancer, the company s...
AstraZeneca says Imfinzi fails in late-stage trial to treat type of lung cancer
AstraZeneca said on Tuesday its blockbuster cancer drug, Imfinzi, failed to improve disease-free survival in a late-stage trial to treat a type of early-stage lung cancer.
AstraZeneca's breast cancer drug combination fails in late-stage trial
AstraZeneca said on Tuesday its breast cancer drug, Truqap, in combination with chemotherapy agent, paclitaxel, did not meet its main goals in a late-stage trial to improve overall survival of patient...
AstraZeneca's lung cancer drug approved by US FDA for combination chemotherapy treatment
AstraZeneca, the largest pharmaceutical group in Britain, announced that the U.S. Food and Drug Administration (FDA) has approved its lung cancer drug, Imfinzi, for use alongside other chemotherapy tr...
IMFINZI® (durvalumab) plus chemotherapy approved in the US for mismatch repair deficient advanced or recurrent endometrial cancer
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca's IMFINZI® (durvalumab) in combination with carboplatin and paclitaxel followed by IMFINZI monotherapy has been approved in the US as treatment for adult...
AstraZeneca Imfinzi plus chemotherapy gets US nod for certain type of endometrial cancer
AstraZeneca said its blockbuster cancer drug Imfinzi combined with chemotherapy has been approved by the U.S. as treatment for adult patients with primary, advanced or recurrent endometrial cancer tha...
FARXIGA approved in the US for the treatment of pediatric type-2 diabetes
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca's FARXIGA® (dapagliflozin) has been approved by the US Food and Drug Administration (FDA) to improve glycemic control in pediatric patients with type-2 d...
TAGRISSO® (osimertinib) granted Priority Review in the US for patients with unresectable, Stage III EGFR-mutated lung cancer
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca's supplemental New Drug Application (sNDA) for TAGRISSO® (osimertinib) has been accepted and granted Priority Review in the US for the treatment of adult...
Healthy Returns: Drugmakers release promising cancer drug data – and AstraZeneca wins big
Drugmakers released cancer data at ASCO, with AstraZeneca taking center stage. A report found that digital physical therapy tools provide clinical benefits.
Nucleus RadioPharma Secures Series A Extension Funding with AstraZeneca Investment
ROCHESTER, Minn.--(BUSINESS WIRE)--Nucleus RadioPharma, the world's first fully integrated development, manufacturing, and supply chain organization for radiopharmaceuticals, today announced the closi...
We're in a difficult business but have the right level of confidence, says AstraZeneca CEO
AstraZeneca CEO Pascal Soriot joins 'Mad Money' host Jim Cramer to talk its lung cancer treatment, late stage drug development, and more.
AstraZeneca CEO Pascal Soriot goes one-on-one with Jim Cramer
AstraZeneca CEO Pascal Soriot joins 'Mad Money' host Jim Cramer to talk its lung cancer treatment, late stage drug development, and more.
Why CEO AstraZeneca believes the pharmaceutical company can almost double revenues by 2030
In a Tuesday interview with CNBC's Jim Cramer, AstraZeneca CEO Pascal Soriot explained why the drug maker believes it can almost double revenues by the end of the decade. AstraZeneca announced in late...
AbelZeta announces clinical data showing preliminary anti-tumor activity for C-CAR031, an armored autologous GPC3 CAR-T, in patients with advanced hepatocellular carcinoma, at ASCO Annual Meeting 2024
CAR031 study at 9.03-mo median follow up achieves disease control rate (DCR) of 91.3% and objective response rate (ORR) of 56.5% for patients across all dose levels (DLs) and ORR of 75.0% at DL4 ROCKV...
Cramer's Stop Trading: AstraZeneca
CNBC's Jim Cramer explains why he is keeping an eye on shares of AstraZeneca.
TAGRISSO® (osimertinib) reduced the risk of disease progression or death by 84% in patients with unresectable, Stage III EGFR-mutated lung cancer vs. placebo in LAURA Phase III trial
WILMINGTON, Del.--(BUSINESS WIRE)--Positive results from the LAURA Phase III trial showed AstraZeneca's TAGRISSO® (osimertinib) demonstrated a statistically significant and highly clinically meaningfu...
IMFINZI® (durvalumab) is the first and only immunotherapy to show survival benefit in limited-stage small cell lung cancer in global Phase III trial, reducing the risk of death by 27% vs. placebo
WILMINGTON, Del.--(BUSINESS WIRE)--Positive results from the ADRIATIC Phase III trial showed AstraZeneca's IMFINZI® (durvalumab) demonstrated statistically significant and clinically meaningful improv...
ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a median progression-free survival of 13.2 months in HR-positive, HER2-low and HER2-ultralow metastatic breast cancer following one or more lines of endocrine therapy
WILMINGTON, Del.--(BUSINESS WIRE)--Detailed positive results from the DESTINY-Breast06 Phase III trial showed that ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a statistically significant a...
ENHERTU® Demonstrated a Median Progression-Free Survival of 13.2 Months in HR Positive, HER2 Low and HER2 Ultralow Metastatic Breast Cancer Following One or More Lines of Endocrine Therapy
TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--ENHERTU Demonstrated a Median PFS of 13.2 Months in HR Positive, HER2 Low and HER2 Ultralow mBC Following One or More Lines of Endocrine Therapy.
Compugen to Receive Milestone Payment Triggered by Dosing of First Patient in the Second Phase 3 Trial Evaluating Rilvegostomig
Phase 3 trial evaluating rilvegostomig as monotherapy and in combination with AstraZeneca and Daiichi Sankyo's datopotamab deruxtecan in first-line nonsquamous non-small cell lung cancer Broadening th...
AstraZeneca started at buy at Goldman, which rates GSK a neutral
Goldman Sachs started coverage of AstraZeneca at buy as it rated rival pharmaceutical company GSK a neutral.